JP6947642B2 - 抗がん性融合ポリペプチド - Google Patents

抗がん性融合ポリペプチド Download PDF

Info

Publication number
JP6947642B2
JP6947642B2 JP2017560331A JP2017560331A JP6947642B2 JP 6947642 B2 JP6947642 B2 JP 6947642B2 JP 2017560331 A JP2017560331 A JP 2017560331A JP 2017560331 A JP2017560331 A JP 2017560331A JP 6947642 B2 JP6947642 B2 JP 6947642B2
Authority
JP
Japan
Prior art keywords
ser
arg
lys
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017560331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519803A5 (cg-RX-API-DMAC7.html
JP2018519803A (ja
Inventor
マーロン ヒンナー
マーロン ヒンナー
アイバ ラシダ シハム ベル
アイバ ラシダ シハム ベル
クリスティーヌ ローテ
クリスティーヌ ローテ
シェーン オルヴィル
シェーン オルヴィル
コリンナ シュロッサー
コリンナ シュロッサー
Original Assignee
ピエリス ファーマシューティカルズ ゲーエムベーハー
ピエリス ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエリス ファーマシューティカルズ ゲーエムベーハー, ピエリス ファーマシューティカルズ ゲーエムベーハー filed Critical ピエリス ファーマシューティカルズ ゲーエムベーハー
Publication of JP2018519803A publication Critical patent/JP2018519803A/ja
Publication of JP2018519803A5 publication Critical patent/JP2018519803A5/ja
Application granted granted Critical
Publication of JP6947642B2 publication Critical patent/JP6947642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017560331A 2015-05-18 2016-05-18 抗がん性融合ポリペプチド Active JP6947642B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15167927 2015-05-18
EP15167927.1 2015-05-18
EP16150508.6 2016-01-08
EP16150508 2016-01-08
PCT/EP2016/061071 WO2016184882A1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide

Publications (3)

Publication Number Publication Date
JP2018519803A JP2018519803A (ja) 2018-07-26
JP2018519803A5 JP2018519803A5 (cg-RX-API-DMAC7.html) 2019-06-20
JP6947642B2 true JP6947642B2 (ja) 2021-10-13

Family

ID=56134305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560331A Active JP6947642B2 (ja) 2015-05-18 2016-05-18 抗がん性融合ポリペプチド

Country Status (22)

Country Link
US (2) US10913778B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219535A1 (cg-RX-API-DMAC7.html)
JP (1) JP6947642B2 (cg-RX-API-DMAC7.html)
KR (1) KR102685748B1 (cg-RX-API-DMAC7.html)
CN (1) CN108112253B (cg-RX-API-DMAC7.html)
AU (1) AU2016262845B2 (cg-RX-API-DMAC7.html)
CA (1) CA2980838A1 (cg-RX-API-DMAC7.html)
DK (1) DK3298030T5 (cg-RX-API-DMAC7.html)
ES (1) ES2938525T3 (cg-RX-API-DMAC7.html)
FI (1) FI3298030T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230145T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061108T2 (cg-RX-API-DMAC7.html)
LT (1) LT3298030T (cg-RX-API-DMAC7.html)
MX (1) MX390894B (cg-RX-API-DMAC7.html)
PL (1) PL3298030T3 (cg-RX-API-DMAC7.html)
RS (1) RS64002B1 (cg-RX-API-DMAC7.html)
RU (2) RU2754466C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201707426SA (cg-RX-API-DMAC7.html)
SI (1) SI3298030T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300026T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016184882A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706061B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
DK3292137T3 (da) * 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
JP7108535B2 (ja) 2015-07-15 2022-07-28 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に特異的な新規タンパク質
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MX2019007795A (es) * 2017-01-03 2019-08-16 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
US11591398B2 (en) 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
KR20190104409A (ko) * 2017-01-18 2019-09-09 피어이스 파마슈티컬즈 게엠베하 Lag-3에 대하여 결합 친화성을 갖는 리포칼린 뮤테인
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
KR20200083574A (ko) * 2017-11-13 2020-07-08 크레센도 바이오로직스 리미티드 Cd137 및 psma에 결합하는 분자
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
US12285410B2 (en) 2018-03-26 2025-04-29 4Sc Ag Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy
KR20210040103A (ko) * 2018-07-31 2021-04-12 피어이스 파마슈티컬즈 게엠베하 Cd137 및 pd-l1에 특이적인 신규한 융합 단백질
CA3124441A1 (en) * 2019-02-26 2020-09-03 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
CA3127973A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
EP3952996A1 (en) * 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
KR20200124176A (ko) * 2019-04-23 2020-11-02 주식회사 엘지화학 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드
UA129329C2 (uk) 2019-06-25 2025-03-19 Гіліад Сайєнсіз, Інк. ЗЛИТІ БІЛКИ FLT3L-Fc
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN115960242B (zh) * 2021-09-09 2023-10-17 广东东阳光药业股份有限公司 抗癌结合分子及其应用
KR20250071257A (ko) * 2022-09-21 2025-05-21 씨젠 인크. Cd137 및 cd228에 특이적인 신규한 융합 단백질

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
KR20010052622A (ko) 1998-06-08 2001-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2002024866A2 (en) 2000-09-21 2002-03-28 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
CN101516907B (zh) 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
JP5608368B2 (ja) 2006-08-01 2014-10-15 ピエリス アーゲー 涙リポカリンの突然変異タンパク質およびそれを得るための方法
WO2009012394A1 (en) 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
RU2564125C2 (ru) 2009-12-07 2015-09-27 Пирис Аг Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени
SG187695A1 (en) 2010-08-16 2013-03-28 Pieris Ag Binding proteins for hepcidin
DK2614082T3 (en) 2010-09-09 2018-11-26 Pfizer 4-1BB BINDING MOLECULES
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
RU2015126651A (ru) * 2012-12-10 2017-01-16 Фред Хатчинсон Кэнсер Рисёрч Сентер Способы скрининга
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN107460201A (zh) * 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
KR102568808B1 (ko) * 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 면역활성화 항원 결합 분자
CA2973640A1 (en) 2015-01-28 2016-08-04 Rachida Siham Bel Aiba Novel proteins specific for angiogenesis
CA2976687A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
BR112017020434A2 (pt) * 2015-05-04 2018-06-26 Pieris Pharmaceuticals Gmbh polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
KR20180008649A (ko) * 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
WO2016184882A1 (en) 2016-11-24
LT3298030T (lt) 2023-02-27
EP3298030B1 (en) 2023-01-18
CN108112253A (zh) 2018-06-01
DK3298030T3 (en) 2023-02-06
ZA201706061B (en) 2022-05-25
SG11201707426SA (en) 2017-10-30
AU2016262845A1 (en) 2018-01-04
US10913778B2 (en) 2021-02-09
HRP20230145T1 (hr) 2023-04-28
RU2021119777A (ru) 2021-08-16
DK3298030T5 (en) 2024-10-07
KR102685748B1 (ko) 2024-07-18
FI3298030T3 (fi) 2023-02-22
BR112017020445A2 (pt) 2018-07-03
US11919931B2 (en) 2024-03-05
US20180148485A1 (en) 2018-05-31
SI3298030T1 (sl) 2023-05-31
PL3298030T3 (pl) 2023-05-08
EP4219535A1 (en) 2023-08-02
HUE061108T2 (hu) 2023-05-28
MX2017014716A (es) 2018-06-28
SMT202300026T1 (it) 2023-03-17
CN108112253B (zh) 2022-09-23
RS64002B1 (sr) 2023-03-31
ES2938525T3 (es) 2023-04-12
MX390894B (es) 2025-03-21
US20210403516A1 (en) 2021-12-30
CA2980838A1 (en) 2016-11-24
RU2017135539A (ru) 2019-06-18
JP2018519803A (ja) 2018-07-26
EP3298030A1 (en) 2018-03-28
AU2016262845B2 (en) 2020-07-23
KR20180002855A (ko) 2018-01-08
RU2017135539A3 (cg-RX-API-DMAC7.html) 2019-11-29
RU2754466C2 (ru) 2021-09-02

Similar Documents

Publication Publication Date Title
JP6947642B2 (ja) 抗がん性融合ポリペプチド
JP6783797B2 (ja) 抗がん融合ポリペプチド
RU2628699C2 (ru) Trail r2-специфические мультимерные скаффолды
JP7476219B2 (ja) Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
TWI837156B (zh) 新穎的cd137及pd-l1特異性融合蛋白
KR20230020443A (ko) 4-1bb 표적화 다량체 면역조절제
BR112017020445B1 (pt) Proteína de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de uma proteína de fusão, uso de uma ou mais proteínas de fusão e composição farmacêutica
HK1249526B (en) Anti-cancer fusion polypeptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210916

R150 Certificate of patent or registration of utility model

Ref document number: 6947642

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250